Media

April 10, 2024 | In the News
NPR BIOTECH NATION: Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.
April 10, 2024 | In the News
ENDPOINTS NEWS: Scientists have long dreamed of creating vaccine-like treatments that could teach the immune system to target tumors. After decades of false starts, that idea is finally getting closer to reality.
March 1, 2024 | Publication

Shubham Pant, Zev A. Wainberg, et al.

Nature Medicine graphical abstract

January 9, 2024

March 1, 2024 | In the News
DRUG TARGET REVIEW: In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted Amphiphile-Immunotherapy to enhance anti-tumour function and eradicate solid tumours.
February 26, 2024 | In the News

BIOSPACE: Finally, Elicio Therapeutics is expected to present the first-ever data from the 7P formulation of its off-the-shelf cancer vaccine candidate, ELI-002 7P, targeting KRAS/NRAS-mutated solid tumors. The interim data will come from the Phase Ia safety arm of the AMPLIFY-7P trial that was initiated in April 2023.